Nootropics & Cognitive Enhancement
Research Hub

Body Protection Compound-157 is a synthetic 15-amino acid peptide fragment derived from a protein found in human gastric juice. Research focuses on its angiogenic properties, tendon and ligament repair, gut health, and neuroprotection. The majority of evidence comes from rodent models, with no completed human clinical trials as of 2026.

GHK-Cu + BPC-157 + TB-500 + KPV blend

A synthetic nootropic and neuroprotective peptide derived from ACTH, studied for cognitive enhancement, stroke recovery, and focus.

Tesamorelin is a synthetic stabilized GHRH analog FDA-approved (as Egrifta) for reducing excess abdominal fat (lipodystrophy) in HIV-infected patients on antiretroviral therapy. It contains the full 44-amino acid sequence of GHRH with a trans-3-hexenoic acid group attached to the N-terminus for enhanced stability. Research also explores its benefits for cognitive function and metabolic health in aging.

Semaglutide is a GLP-1 receptor agonist with 94% amino acid sequence homology to native human GLP-1. FDA-approved as Ozempic (type 2 diabetes, 2017) and Wegovy (chronic weight management, 2021). The STEP trials demonstrated 15–17% mean body weight reduction at 68 weeks with 2.4 mg weekly dosing, establishing it as the leading pharmaceutical treatment for obesity.

MOTS-c is a mitochondrial-derived peptide (MDP) encoded within the mitochondrial genome's 12S rRNA region. Discovered in 2015 by researchers at USC, it represents a paradigm shift in understanding mitochondria as active endocrine signaling organelles. Research focuses on metabolic regulation, insulin sensitivity, exercise mimicry, and longevity, with plasma levels declining with age.

A synthetic anxiolytic and nootropic peptide derived from tuftsin, studied for anxiety, cognitive enhancement, and immune modulation.

PT-141 (Bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist FDA-approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike PDE5 inhibitors (Viagra), PT-141 acts centrally through the nervous system rather than peripherally on blood flow, making it the first approved drug to target sexual desire rather than sexual performance.

Triple monoamine reuptake inhibitor for weight management

Dihexa is a synthetic peptide analogue of the angiotensin IV metabolite LVV-hemorphin-7, developed at Washington State University. It is considered one of the most potent cognitive enhancers ever tested in animal models — reportedly 7 orders of magnitude more potent than BDNF at improving cognitive performance in rodent Alzheimer's models. Exclusively used by the research and biohacking community with no human clinical trial data available.

Master antioxidant tripeptide

Combined nootropic and anxiolytic peptide blend